Patrizia Tosi

Rimini, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications

Correction: Machine learning for prompt estimation of macroseismic intensity from seismometric data in Italy.

Correction: Machine learning for prompt estimation of macroseismic intensity from seismometric data in Italy.

Journal: Scientific reports
Published: March 18, 2026

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

Imaging in Plasma-Cell Neoplasms: Italian Experts' Recommendations.

Journal: European journal of haematology
Published: September 27, 2025

Machine learning for prompt estimation of macroseismic intensity from seismometric data in Italy.

Machine learning for prompt estimation of macroseismic intensity from seismometric data in Italy.

Journal: Scientific reports
Published: September 12, 2025

Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.

Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework.

Journal: BMC cancer
Published: April 17, 2025

PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study.

PNH clones prevalence study in ph-negative myeloproliferative neoplasms: a multicenter Italian study.

Journal: Annals of hematology
Published: March 26, 2025

Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial.

Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial.

Journal: Haematologica
Published: February 11, 2025

Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.

Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.

Journal: The Lancet. Haematology
Published: January 30, 2025

Clinicians' Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy.

Clinicians' Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy.

Journal: Clinical lymphoma, myeloma & leukemia
Published: January 20, 2025

Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial.

Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single-arm FIL-BRB trial.

Journal: British journal of haematology
Published: September 15, 2024

Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi.

Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi.

Journal: Blood advances
Published: September 11, 2024

Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study.

Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study.

Journal: HemaSphere
Published: July 31, 2024

Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.

Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.

Journal: European journal of haematology
Published: July 23, 2024
Showing 1-12 of 54

Last Updated: 09/26/2026